ARK Genomic Revolution ETF
ARKG
213 hedge funds and large institutions have $528M invested in ARK Genomic Revolution ETF in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 39 increasing their positions, 69 reducing their positions, and 33 closing their positions.
9% more capital invested
Capital invested by funds: $482M → $528M (+$45.6M)
6% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 33
0% less funds holding
Funds holding: 214 → 213 (-1)
7% less call options, than puts
Call options by funds: $107M | Put options by funds: $116M
3.25% less ownership
Funds ownership: 53.18% → 49.93% (-3.2%)
43% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$20.2M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.64M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.36M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3.37M |
| 5 |
Two Sigma Investments
New York
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$41.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$16.8M |
| 3 |
Morgan Stanley
New York
|
-$5.23M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$3.25M |
| 5 |
SG Americas Securities
New York
|
-$2.45M |
ARKG Hedge Fund Activity: Q2 2025 in Review
213 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q2 2025, worth a combined $528M — up 9.5% from $482M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ARKG positions and 33 closed out — a net gain of 2 holders — while 39 added to existing stakes and 69 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $20.2M. The largest seller was Citigroup, cutting an estimated $41.4M.
- 213 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q2 2025, down from 214 in Q1 2025.
- Funds reported $528M of ARK Genomic Revolution ETF stock for Q2 2025, up 9.5% quarter-over-quarter.
- 35 funds opened new ARK Genomic Revolution ETF positions in Q2 2025 and 33 closed out, a net change of +2 holders.
- The largest ARK Genomic Revolution ETF buyer in Q2 2025 was JP Morgan Chase, an estimated $20.2M added.
- The largest ARK Genomic Revolution ETF seller in Q2 2025 was Citigroup, an estimated $41.4M sold.
Based on aggregated 13F filings for Q2 2025.